Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.

Nucleic acid therapeutics - 1 Jun 2020

Yu Rosie Z, Collins Jon W, Hall Shannon, Ackermann Elizabeth J, Geary Richard S, Monia Brett P, Henry Scott P, Wang Yanfeng

Abstract excerpt

A population pharmacokinetic (PK) and pharmacodynamic (PD) model was developed for inotersen to evaluate exposure-response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (TTR) amyloidosis polyneuropathy (hATTR-PN). Inotersen PK and TTR level (PD) data were composed of one Phase 1 study in healthy subjects, one Phase 2/3 study in hATTR patients, and its one...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Amyloid Neuropathies, Familial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bilirubin

Share to Drug Dosage Calculations

Share to Glomerular Filtration Rate

Share to Neuroprotective Agents

Share to Prealbumin

Share to Serum Albumin

Source

Open in PubMed Open full text

Identifiers

PMID: 32286934
DOI: 10.1089/nat.2019.0822
PMCID: PMC7249474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.PMID 32286934Read ↗

Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosisSemantic proximity Read ↗

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Inotersen: First Global Approval.Semantic proximity Read ↗

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.Semantic proximity Read ↗

Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.Semantic proximity Read ↗

Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy ManagementSemantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosisSemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter FutureSemantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

Treating hereditary transthyretin amyloidosis: Present & future challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.